What a year 2018 turned out to be for the cannabis industry. A stark increase in recreational legalizations, the incredible growth in both industry and research ventures, and the first FDA-approved cannabis-derived drug was announced. Plus much more!
Five different plant pathogens were identified in the crown tissues of wilted plants highlighting the need for better environmental controls and cultivation practices for outdoor grows.
Hemp represents a tangible opportunity for future explosive market growth. Under the Farm Bill hemp cultivation will be allowed more broadly, and the product will have free movement across state borders.
Apart from the obvious adverse effects these fungal infections have on plant crops, some can cause adverse health effects in humans.
Microbes can be introduced to cannabis products during the growing and processing phases. This is a challenging area for microbiologists, and requires them to implement a variety of techniques in order to create medical-grade cannabis.
Unveiling the genetic map and key genes within the cannabis genome will enable the development of bespoke cannabis strains with controlled cannabinoid content.
Demand for cannabis is outweighing supply in Canada, meaning consumer disappointment and a possible resurgence in black market product.
With cannabis cultivation taking off in a big way, safety considerations have never been so important.
Data reveals that 43 percent of cannabis samples tested contained either banned pesticides or illegal levels of state-approved pesticides.
Hydroponically grown cannabis relies on a re-circulated solution that provides nutrients for growth. Infections within the system can be devastating; we discuss why monitoring and sterilization are key.